abrdn plc raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 69.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,060 shares of the company's stock after purchasing an additional 53,060 shares during the quarter. abrdn plc owned approximately 0.14% of NewAmsterdam Pharma worth $2,142,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of NAMS. Banque Cantonale Vaudoise bought a new position in NewAmsterdam Pharma in the 2nd quarter valued at about $38,000. Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma during the second quarter valued at approximately $194,000. Wolverine Asset Management LLC boosted its position in NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock valued at $298,000 after buying an additional 8,394 shares in the last quarter. Sei Investments Co. grew its holdings in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company's stock worth $472,000 after acquiring an additional 8,087 shares during the last quarter. Finally, StemPoint Capital LP acquired a new stake in NewAmsterdam Pharma in the first quarter valued at $1,900,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at NewAmsterdam Pharma
In other news, CAO Louise Frederika Kooij sold 45,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 19.50% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Needham & Company LLC assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, August 28th. They set a "buy" rating and a $36.00 price objective on the stock. Piper Sandler reiterated an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of "Buy" and a consensus price target of $33.80.
Read Our Latest Report on NAMS
NewAmsterdam Pharma Stock Performance
Shares of NAMS traded up $1.03 on Tuesday, reaching $19.06. 193,462 shares of the company's stock traded hands, compared to its average volume of 255,226. The stock's 50 day simple moving average is $17.23 and its two-hundred day simple moving average is $18.45. NewAmsterdam Pharma has a 52-week low of $8.64 and a 52-week high of $26.35.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million for the quarter, compared to the consensus estimate of $2.20 million. As a group, sell-side analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current year.
NewAmsterdam Pharma Company Profile
(
Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
